Ongoing Clinical Studies in Bladder Cancer
Cretostimogene grenadenorepvec is currently being evaluated in multiple studies including Phase 1b/2, Phase 2, and and two Phase 3 studies in the U.S. and Canada in BCG unresponsive, Intermediate-Risk and MIBC. One study is actively recruiting. Studies are on-going in South Korea, Japan, China, Taiwan, Australia, and Canada.
TRIAL TITLE
Phase 2 Study in BCG-unresponsive NMIBC
Phase 2, US only
Phase 3 Study in BCG-unresponsive NMIBC
Phase 3, Global (US, Japan, South Korea, Taiwan, Australia, Canada)
Phase 2 Combo with Pembrolizumab
Phase 2, Global (US, South Korea)
CORE-002
Phase 1 Study With Nivolumab Ineligible Cisplatin with MIBC
Phase 1b/2, US Only
Recruiting
Phase 3 Study
Intermediate-Risk
and Canada
Recruiting
Intermediate-Risk
Patients and Urologists interested in participating should contact:
JoAnn Horn
phone: 516-456-1415
joann.horn@CGOncology.com.
Expanded Patient Access
How Patients can Access the on-going Studies
CG Oncology is currently focused on conducting clinical research that evaluates the safety and effectiveness of investigational cretostimogene grenadenorepvec (CG0070) in Non-Muscle Invasive Bladder Cancer (NMIBC). Our clinical trials program is the primary way for interested patients to access cretostimogene grenadenorepvec at this time. We encourage patients to speak with their healthcare providers about participating in a clinical trial and may also find information on our current clinical studies on on-going clinical trials
As a general policy, CG Oncology does not anticipate providing investigational medicines to patients until our clinical data suggests that the therapy has provided evidence of safety and efficacy as defined by the U.S. Food and Drug Administration. As a result, CG Oncology believes the most appropriate way to access our investigational therapy is through participating in one of our clinical trials.
Partners
CG Oncology is eager to partner with others who share our passion for improving patients and their loved one’s lives.
